The NAFTA Generics industry guide provides top-line qualitative and quantitative summary information including: market size (value and volume 2011-15, and forecast to 2020). The guide also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Features and benefits
Save time carrying out entry-level research by identifying the size, growth, and leading players in the NAFTA generics market
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the NAFTA generics market
Leading company profiles reveal details of key generics market players’ NAFTA operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the NAFTA generics market with five year forecasts
Compares data from the US, Canada and Mexico, alongside individual chapters on each country
The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The generics industry within the NAFTA countries had a total market value of $105.4 billion in 2015.The Mexico was the fastest growing country, with a CAGR of 14.2% over the 2011-15 period.
Within the generics industry, the US is the leading country among the NAFTA bloc, with market revenues of $94.0 billion in 2015. This was followed by Mexico and Canada, with a value of $6.6 and $4.9 billion, respectively.
The US is expected to lead the generics industry in the NAFTA bloc, with a value of $128.0 billion in 2020, followed by Mexico and Canada with expected values of $11.1 and $5.3 billion, respectively.
Your key questions answered
What was the size of the NAFTA generics market by value in 2015?
What will be the size of the NAFTA generics market in 2020?
What factors are affecting the strength of competition in the NAFTA generics market?
How has the market performed over the last five years?
How large is the NAFTA generics market in relation to its regional counterparts?